The Pfizer Quality Improvement Competitive Grant Program – Improving Precision Oncology Care Through Molecular Diagnostic Integration and Data Quality Improvement supports initiatives in Kazakhstan that measurably improve the collection, linkage, standardization, and use of oncology data across the patient pathway. Projects should focus on integrating molecular diagnostic results with treatment processes and selected outcomes to enable more timely, consistent, and evidence-informed care delivery and health system planning. The program is intended to strengthen data quality and data-enabled care processes in selected advanced cancers where precision diagnostics are critical to clinical decision-making.

Overview

This competitive grant program invites proposals for data-driven quality improvement (QI) projects that strengthen the diagnostic-to-treatment pathway through improved data capture, integration, governance, and reporting. Projects must focus on quality improvement initiatives in adult advanced lung cancer (ALK+ mNSCLC), metastatic breast cancer (HR+ HER2-/HER2+ and BRCA1/2-associated mBC), and metastatic prostate cancer (mCRPC and mCSPC guided by HRR/DNA-repair testing). Clinical research or evaluation of therapeutic or diagnostic efficacy is explicitly excluded; projects must focus solely on care processes and data quality.

The geographic scope is Kazakhstan, and national or regional projects are welcome. Multi-site collaborations are encouraged.

Funding and Benefits

Individual projects requesting up to 5,000,000–10,000,000 KZT will be considered. The expected project duration is 1–2 years. Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs. Grants will be distributed following a fully executed agreement and submission of final protocol, documentation of IRB/IEC approval, regulatory approval, exemption, or waiver as applicable.

Eligibility

The following types of organizations may apply: medical, dental, nursing, allied health, and pharmacy professional schools; healthcare institutions (both large and small); professional organizations; government agencies; and other entities with a mission related to healthcare improvement. Only organizations are eligible to receive grants, not individuals or independent medical practice groups not affiliated with a hospital, academic institution, or professional society.

Collaborations within institutions (e.g., between departments or inter-professional) and between different institutions, organizations, or associations are encouraged. All partners must have a relevant role, and the requesting organization must have a key role in the project. The applicant must be the Project Lead or Principal Investigator (PI) or an authorized designee. The Project Lead or PI must be an employee or contractor of the requesting organization. The requesting organization must be legally able to receive award funding directly from Pfizer International LLC.

Research Areas and Activities

Eligible activities include the following focus areas:

• Improving data quality and linkage (core focus): Establishing or enhancing structured datasets that link molecular diagnostics with treatment patterns, care-process timelines, and selected indicators, supported by standardized SOPs, data dictionaries, and workflows to ensure complete, timely capture and electronic linkage of biomarker results to treatment records across sites.
• Diagnostic pathway and testing process improvement: Quality improvement interventions to enhance appropriate molecular testing rates, turnaround times, and documentation completeness, while strengthening coordination between oncology centers, pathology and molecular laboratories, and referral networks through standardized requisitions, reflex testing pathways, and tracking tools.
• Individual-level data integration for population-level insight: Improving completeness and consistency of epidemiologic data through integration of hospital, laboratory, and registry sources, supported by dashboards and routine reports to monitor care pathways, inform service planning, and identify system bottlenecks.

Projects should focus on QI initiatives that enhance molecular and clinical data quality and interoperability, streamline the diagnostic-to-treatment pathway by reducing delays and variability, and enable actionable, integrated reporting to inform continuous improvement and health system planning.

Application Process

Applications must be submitted through the online portal at www.cybergrants.com/pfizer/QI. First-time users should click "Create your password". Click the "Start A New Quality Improvement Grant Application" button. Complete all required sections of the online application and upload the full proposal in the Proposal or Protocol field. In the application, for the question "Competitive Grant?" select "Yes", select the Primary Area of Interest "Oncology – General/Non-specific/Other – QI", and select the Competitive Grant Program Name "2026 ONC KZ Improving Precision Oncology Care QI".

Full proposals should be single-spaced using Calibri 12-point font with 1-inch margins and must not exceed 15 pages (exclusive of references). The proposal must address goals and objectives, assessment of need, target audience, project design and methods, innovation, evaluation and outcomes, anticipated timeline, additional information, organization detail, and budget detail in KZT.

Deadline and Timeline

• RFP Release Date: 21 April 2026
• Submission Deadline: 2 June 2026, 23:59 Eastern Standard Time (New York, GMT -5)
• Anticipated Grant Award Notification: August 2026
• Anticipated Project Start Date: October 2026
• Anticipated Project End Date: October 2028

Applications submitted after the due date will not be reviewed.

Contact Information

For questions regarding this Request for Proposals, direct inquiries in writing to the designated Grant Officer, Neha Singhal, at GlobalMedicalGrants@pfizer.com with the subject line "Improving Precision Oncology Care Through Molecular Diagnostic Integration and Data Quality Improvement – 21APR2026". For technical difficulties with the submission website, use the "Technical Questions" link at the bottom of the page in Cybergrants.